Evolving Therapeutics

Evolving Therapeutics is an innovative biotechnology startup specializing in the development of bacteriophage-based therapies to combat multidrug-resistant bacterial infections affecting human, animal, and plant health. Founded in 2023 as a spin-off from the University of Valencia, the company leverages cutting-edge research in phage therapy to offer sustainable, targeted alternatives to traditional antibiotics and chemical treatments.

The company’s core mission is to address the growing global threat posed by antimicrobial resistance (AMR), which has rendered many conventional antibiotics ineffective. By harnessing the natural ability of bacteriophages—viruses that specifically infect and destroy bacteria—Evolving Therapeutics aims to develop highly specific, environmentally friendly therapies that can overcome resistant pathogens without harming beneficial microbiota.

One of the company’s flagship projects focuses on combating Xylella fastidiosa, a destructive bacterial pathogen severely impacting crops in the Balearic Islands and other regions. This pioneering initiative marks the first pilot application of phage therapy in agriculture in Spain, showcasing the potential of phages to protect plants while reducing reliance on harmful pesticides.

Evolving Therapeutics has gained recognition for its innovative approach, securing notable investments including a €100,000 funding round from Angels Capital, the investment firm led by Juan Roig. This support has enabled the expansion of its laboratory facilities and research team, strengthening its capacity to innovate and scale its solutions.

With a strong commitment to science, sustainability, and health, Evolving Therapeutics is positioned at the forefront of phage therapy development, offering promising new tools to tackle one of the most urgent challenges of modern medicine and agriculture.